Search

Your search keyword '"Setinek, Ulrike"' showing total 140 results
Start Over Author "Setinek, Ulrike"
140 results on '"Setinek, Ulrike"'

1. The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers

Author

Popper, Helmut H., Gruber-Mösenbacher, Ulrike, Pall, Georg, Müllauer, Leonhard, Hochmair, Maximilian, Krenbek, Dagmar, Brcic, Luka, Schmitz, Katja, Lamprecht, Bernd, Eckmayr, Josef, Hilbe, Wolfgang, Hutarew, Georg, Errhalt, Peter, Kolb, Rainer, Pirker, Robert, Setinek, Ulrike, Webersinke, Gerald, Absenger, Gudrun, Hernler, Tamara, Rauter, Markus, and Wasicky, Richard

Published
2020
Full Text
View/download PDF

2. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe

Author

Keppens, Cleo, Palma, John F., Das, Partha M., Scudder, Sidney, Wen, Wei, Normanno, Nicola, van Krieken, J. Han, Sacco, Alessandra, Fenizia, Francesca, Gonzalez de Castro, David, Hönigschnabl, Selma, Kern, Izidor, Lopez-Rios, Fernando, Lozano, Maria D., Marchetti, Antonio, Halfon, Philippe, Schuuring, Ed, Setinek, Ulrike, Sorensen, Boe, Taniere, Phillipe, Tiemann, Markus, Vosmikova, Hana, and Dequeker, Elisabeth M.C.

Published
2018
Full Text
View/download PDF

6. Data from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

Author

Fischer, Hendrik, primary, Taylor, Ninon, primary, Allerstorfer, Sigrid, primary, Grusch, Michael, primary, Sonvilla, Gudrun, primary, Holzmann, Klaus, primary, Setinek, Ulrike, primary, Elbling, Leonilla, primary, Cantonati, Heidelinde, primary, Grasl-Kraupp, Bettina, primary, Gauglhofer, Christine, primary, Marian, Brigitte, primary, Micksche, Michael, primary, and Berger, Walter, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Fig. S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

Author

Fischer, Hendrik, primary, Taylor, Ninon, primary, Allerstorfer, Sigrid, primary, Grusch, Michael, primary, Sonvilla, Gudrun, primary, Holzmann, Klaus, primary, Setinek, Ulrike, primary, Elbling, Leonilla, primary, Cantonati, Heidelinde, primary, Grasl-Kraupp, Bettina, primary, Gauglhofer, Christine, primary, Marian, Brigitte, primary, Micksche, Michael, primary, and Berger, Walter, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

Author

Fischer, Hendrik, primary, Taylor, Ninon, primary, Allerstorfer, Sigrid, primary, Grusch, Michael, primary, Sonvilla, Gudrun, primary, Holzmann, Klaus, primary, Setinek, Ulrike, primary, Elbling, Leonilla, primary, Cantonati, Heidelinde, primary, Grasl-Kraupp, Bettina, primary, Gauglhofer, Christine, primary, Marian, Brigitte, primary, Micksche, Michael, primary, and Berger, Walter, primary

Published
2023
Full Text
View/download PDF

9. Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

Author

Popper, Helmut H., Gruber-Mösenbacher, Ulrike, Hutarew, Georg, Hochmair, Maximilian, Absenger, Gudrun, Brcic, Luka, Müllauer, Leonhard, Dekan, Gerhard, Setinek, Ulrike, Krenbek, Dagmar, Vesely, Michael, Pirker, Robert, Hilbe, Wolfgang, Kolb, Rainer, Webersinke, Gerald, Hernler, Tamara, Pall, Georg, Lax, Sigurd, and Mohn-Staudner, Andrea

Published
2016
Full Text
View/download PDF

10. Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study

Author

Illini, Oliver, primary, Fabikan, Hannah, additional, Hochmair, Maximilian Johannes, additional, Weinlinger, Christoph, additional, Krenbek, Dagmar, additional, Brcic, Luka, additional, Setinek, Ulrike, additional, Terbuch, Angelika, additional, Absenger, Gudrun, additional, Konjić, Selma, additional, and Valipour, Arschang, additional

Published
2022
Full Text
View/download PDF

11. Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients

Author

Holzknecht, Arnulf, primary, Illini, Oliver, additional, Hochmair, Maximilian J., additional, Krenbek, Dagmar, additional, Setinek, Ulrike, additional, Huemer, Florian, additional, Bitterlich, Erwin, additional, Kaindl, Christoph, additional, Getman, Vladyslav, additional, Akan, Ahmet, additional, Weber, Michael, additional, Leobacher, Gunther, additional, Valipour, Arschang, additional, Mueller, Michael R., additional, and Watzka, Stefan B., additional

Published
2022
Full Text
View/download PDF

13. Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

Author

Popper, Helmut H., Gruber-Moesenbacher, Ulrike, Müllauer, Leonhard, Hutarew, Georg, Vesely, Michael, Pirker, Robert, Hilbe, Wolfgang, Ploner, Ferdinand, Setinek, Ulrike, Hulla, Wolfgang, Maier, Hans, Sterlacci, William, Kirchbacher, Klaus, Kolb, Rainer, Hochmair, Maximilian, Webersinke, Gerald, Stacher, Elvira, Grabher, Patricia, and Hernler, Tamara

Published
2013
Full Text
View/download PDF

14. Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy

Author

Schelch, Karin, Hoda, Mir A., Klikovits, Thomas, Münzker, Julia, Ghanim, Bahil, Wagner, Christina, Garay, Tamas, Laszlo, Viktoria, Setinek, Ulrike, Dome, Balazs, Filipits, Martin, Pirker, Christine, Heffeter, Petra, Selzer, Edgar, Tovari, Jozsef, Torok, Szilvia, Kenessey, Istvan, Holzmann, Klaus, Grasl-Kraupp, Bettina, Marian, Brigitte, Klepetko, Walter, Berger, Walter, Hegedus, Balazs, and Grusch, Michael

Published
2014
Full Text
View/download PDF

18. Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Author

Hochmair, Maximilian J., primary, Fabikan, Hannah, additional, Illini, Oliver, additional, Weinlinger, Christoph, additional, Setinek, Ulrike, additional, Krenbek, Dagmar, additional, Prosch, Helmut, additional, Rauter, Markus, additional, Schumacher, Michael, additional, Wöll, Ewald, additional, Wass, Romana, additional, Brehm, Elmar, additional, Absenger, Gudrun, additional, Bundalo, Tatjana, additional, Errhalt, Peter, additional, Urban, Matthias, additional, and Valipour, Arschang, additional

Published
2020
Full Text
View/download PDF

20. Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion–Positive Metastatic Lung Cancer

Author

Hochmair, Maximilian Johannes, primary, Setinek, Ulrike, additional, Krenbek, Dagmar, additional, Fazekas, Andreas, additional, Illini, Oliver, additional, Weinlinger, Christoph, additional, Draxler, Hermann, additional, Marcher, Markus, additional, Valipour, Arschang, additional, Müllauer, Leonhard, additional, and Beer, Lucian, additional

Published
2020
Full Text
View/download PDF

22. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of the cobas EGFR Mutation Test v2 in Europe

Author

Keppens, Cleo, Palma, John, Das, Partha, Scudder, Sidney, Wen, Wei, Normanno, Nicola, van Krieken, Han, Sacco, Alessandra, Fenizia, Francesca, Gonzalez de Castro, David, Hönigschnabl, Selma, Kern, Izidor, Lopez-Rios, Fernando, Lozano, Maria, Marchetti, Antonio, Halfon, Philippe, Schuuring, Ed, Setinek, Ulrike, Sorensen, Boe, Taniere, Phillipe, Tiemann, Markus, Vosmikova, Hana, and Dequeker, Els

Abstract

Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in non-small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of tumor tissue. This study evaluated the interlaboratory performance and reproducibility of a real-time PCR EGFR mutation test (cobas EGFR Mutation Test v2) to detect EGFR variants in plasma. Fourteen laboratories received two identical panels of 27 single-blinded plasma samples. Samples were wild type or spiked with plasmid DNA to contain seven common EGFR variants at six predefined concentrations from 50 to 5000 copies per milliliter. The circulating tumor DNA was extracted by a cell-free circulating DNA sample preparation kit (cobas cfDNA Sample Preparation Kit), followed by duplicate analysis with the real-time PCR EGFR mutation test (Roche Molecular Systems, Pleasanton, CA). Lowest sensitivities were obtained for the c.2156G>C p.(Gly719Ala) and c.2573T>G p.(Leu858Arg) variants for the lowest target copies. For all other variants, sensitivities varied between 96.3% and 100.0%. All specificities were 98.8% to 100.0%. Coefficients of variation indicated good intralaboratory and interlaboratory repeatability and reproducibility but increased for decreasing concentrations. Prediction models revealed a significant correlation for all variants between the predefined copy number and the observed semiquantitative index values, which reflect the samples' plasma mutation load. This study demonstrates an overall robust performance of the real-time PCR EGFR mutation test kit in plasma. Prediction models may be applied to estimate the plasma mutation load for diagnostic or research purposes. ispartof: The Journal of Molecular Diagnostics vol:20 issue:17 pages:30514-30517 ispartof: location:United States status: published

Published
2018

23. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe

Author

Keppens, Cleo, Palma, John, Das, Partha, Scudder, Sidney, Wen, Wei, Normanno, Nicola, van Krieken, Han J. J. M., Sacco, Alessandra, Fenizia, Francesca, Gonzalez de Castro, David, Hönigschnabl, Selma, Kern, Izidor, Lopez-Rios, Fernando, Lozano, Maria D., Marchetti, Antonio, Halfon, Philippe, Schuuring, Ed, Setinek, Ulrike, Sorensen, Boe, Taniere, Phillipe, Tiemann, Markus, Vosmikova, Hana, and Dequeker, Elisabeth

Subjects
udc:616-006, molecular testing, molekularno testiranje, Models, Genetic, EGFR, plazma, Gene Dosage, Real-Time Polymerase Chain Reaction, Sensitivity and Specificity, Circulating Tumor DNA, ErbB Receptors, Europe, Bias, Mutation, Humans, non-small cell lung cancer, plasma, Algorithms, nedrobnocelični pljučni rak
Abstract

Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in non-small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of tumor tissue. This study evaluated the interlaboratory performance and reproducibility of a real-time PCR EGFR mutation test (cobas EGFR Mutation Test v2) to detect EGFR variants in plasma. Fourteen laboratories received two identical panels of 27 single-blinded plasma samples. Samples were wild type or spiked with plasmid DNA to contain seven common EGFR variants at six predefined concentrations from 50 to 5000 copies per milliliter. The circulating tumor DNA was extracted by a cell-free circulating DNA sample preparation kit (cobas cfDNA Sample Preparation Kit), followed by duplicate analysis with the real-time PCR EGFR mutation test (Roche Molecular Systems, Pleasanton, CA). Lowest sensitivities were obtained for the c.2156G>C p.(Gly719Ala) and c.2573T>G p.(Leu858Arg) variants for the lowest target copies. For all other variants, sensitivities varied between 96.3% and 100.0%. All specificities were 98.8% to 100.0%. Coefficients of variation indicated good intralaboratory and interlaboratory repeatability and reproducibility but increased for decreasing concentrations. Prediction models revealed a significant correlation for all variants between the predefined copy number and the observed semiquantitative index values, which reflect the samples' plasma mutation load. This study demonstrates an overall robust performance of the real-time PCR EGFR mutation test kit in plasma. Prediction models may be applied to estimate the plasma mutation load for diagnostic or research purposes. Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in non-small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of tumor tissue. This study evaluated the interlaboratory performance and reproducibility of a real-time PCR EGFR mutation test (cobas EGFR Mutation Test v2) to detect EGFR variants in plasma. Fourteen laboratories received two identical panels of 27 single-blinded plasma samples. Samples were wild type or spiked with plasmid DNA to contain seven common EGFR variants at six predefined concentrations from 50 to 5000 copies per milliliter. The circulating tumor DNA was extracted by a cell-free circulating DNA sample preparation kit (cobas cfDNA Sample Preparation Kit), followed by duplicate analysis with the real-time PCR EGFR mutation test (Roche Molecular Systems, Pleasanton, CA). Lowest sensitivities were obtained for the c.2156G>C p.(Gly719Ala) and c.2573T>G p.(Leu858Arg) variants for the lowest target copies. For all other variants, sensitivities varied between 96.3% and 100.0%. All specificities were 98.8% to 100.0%. Coefficients of variation indicated good intralaboratory and interlaboratory repeatability and reproducibility but increased for decreasing concentrations. Prediction models revealed a significant correlation for all variants between the predefined copy number and the observed semiquantitative index values, which reflect the samples' plasma mutation load. This study demonstrates an overall robust performance of the real-time PCR EGFR mutation test kit in plasma. Prediction models may be applied to estimate the plasma mutation load for diagnostic or research purposes.

Published
2017
Full Text
View/download PDF

25. P1.04-001 EGFR, EML4-ALK, ROS 1 and BRAF Testing in Austrian Patients with NSCLC: A Multicenter Study

Author

Holzer, Sophia, primary, Hochmair, Maximilian, additional, Setinek, Ulrike, additional, Krenbek, Dagmar, additional, Fabikan, Hannah, additional, Rumbold, Rosemarie, additional, Mohn-Staudner, Andrea, additional, Kirchbacher, Klaus, additional, Arns, Madeleine, additional, Bundalo, Tatjana, additional, Patocka, Kurt, additional, and Burghuber, Otto, additional

Published
2017
Full Text
View/download PDF

26. P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC

Author

Buder, Anna, primary, Hochmair, Maximilian, additional, Holzer, Sophia, additional, Mohn-Staudner, Andrea, additional, Errhalt, Peter, additional, Bundalo, Tatjana, additional, Schenk, Peter, additional, Setinek, Ulrike, additional, Burghuber, Otto, additional, Pirker, Robert, additional, and Filipits, Martin, additional

Published
2017
Full Text
View/download PDF

27. P3.02b-101 EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib

Author

Hochmair, Maximilian, primary, Holzer, Sophia, additional, Filipits, Martin, additional, Mohn-Staudner, Andrea, additional, Errhalt, Peter, additional, Absenger, Gudrun, additional, Bundalo, Tatjana, additional, Arns, Madeleine, additional, Setinek, Ulrike, additional, Mikes, Romana, additional, Kolb, Rainer, additional, Schumacher, Michael, additional, Zöchbauer-Müller, Sabine, additional, Patocka, Kurt, additional, Haslbauer, Ferdinand, additional, Rudzki, Jakob, additional, and Burghuber, Otto, additional

Published
2017
Full Text
View/download PDF

29. EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.

Author

Hochmair, Maximilian J., primary, Holzer, Sophia, additional, Filipits, Martin, additional, Mohn-Staudner, Andrea, additional, Arns, Madeleine, additional, Errhalt, Peter, additional, Absenger, Gudrun, additional, Koller-Herzog, Ursula, additional, Setinek, Ulrike, additional, Haslbauer, Ferdinand, additional, Korger, Mark A., additional, Patocka, Kurt, additional, Kolb, Rainer, additional, and Burghuber, Otto, additional

Published
2016
Full Text
View/download PDF

31. [Untitled]

Author

Setinek Ulrike, Grisold Wolfgang, and Drlicek Marcus

Subjects
Cancer Research, medicine.medical_specialty, Pathology, Neurology, Carcinosis, business.industry, Cancer, medicine.disease, Lymphoma, Leukemia, Meningeal carcinomatosis, Oncology, medicine, Carcinoma, Neurology (clinical), Sarcoma, business
Abstract

Leptomeningeal carcinomatosis (LC) occurs in solid tumors like breast, lung carcinoma and melanoma, rarely sarcoma and in leukemia and lymphoma. Clinical symptoms of LC often present with differentialdiagnostic problems. The most common presentation are multiple neuraxis syndromes which for didactic reasons are classically considered as central nervous system (CNS), spinal (SP) or cranial nerve (CN) symptoms and signs and appear isolated or more frequently in combinations. It is generally agreed that signs are usually more prominent than symptoms. Only few series focus on monolocular presentation at clinical manifestation. This overview describes the clinical symptoms and signs in patients with LC, the concept of multiple neuraxis lesions, CNS, CN and SP signs and symptoms. Also the problem of new symptoms and signs in patients treated with antineoplastic chemotherapy and radiation is adressed. The study is based on own results and a survey of the present literature.

Published
1998
Full Text
View/download PDF

32. Ilk reactivity and recurrence of pulmonary adenocarcinoma after sleeve resection: a pilot study

Author

Watzka, Stefan B., Setinek, Ulrike, Lax, Franz, Watson, Sonja, Cantonati, Heidi, Weigel, Günter, Müller, Michael R., and Hollaus, Peter H.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Objectives: We have recently shown, that the pattern and natural history of recurrence after bronchoplastic procedures cannot be sufficiently explained by stage and surgical radicality alone; therefore, the search for peculiar genetic characteristics of the primary tumor is justified. Integrin-linked[for full text, please go to the a.m. URL], 16. Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie

Published
2010

34. Detection of EGFRVariants in Plasma

Author

Keppens, Cleo, Palma, John F., Das, Partha M., Scudder, Sidney, Wen, Wei, Normanno, Nicola, van Krieken, J. Han, Sacco, Alessandra, Fenizia, Francesca, Gonzalez de Castro, David, Hönigschnabl, Selma, Kern, Izidor, Lopez-Rios, Fernando, Lozano, Maria D., Marchetti, Antonio, Halfon, Philippe, Schuuring, Ed, Setinek, Ulrike, Sorensen, Boe, Taniere, Phillipe, Tiemann, Markus, Vosmikova, Hana, and Dequeker, Elisabeth M.C.

Abstract

Molecular testing of EGFRis required to predict the response likelihood to targeted therapy in non–small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of tumor tissue. This study evaluated the interlaboratory performance and reproducibility of a real-time PCR EGFRmutation test (cobas EGFR Mutation Test v2) to detect EGFRvariants in plasma. Fourteen laboratories received two identical panels of 27 single-blinded plasma samples. Samples were wild type or spiked with plasmid DNA to contain seven common EGFRvariantsat six predefined concentrations from 50 to 5000 copies per milliliter. The circulating tumor DNA was extracted by a cell-free circulating DNA sample preparation kit (cobas cfDNA Sample Preparation Kit), followed by duplicate analysis with the real-time PCR EGFRmutation test (Roche Molecular Systems, Pleasanton, CA). Lowest sensitivities were obtained for the c.2156G>C p.(Gly719Ala) and c.2573T>G p.(Leu858Arg) variants for the lowest target copies. For all other variants, sensitivities varied between 96.3% and 100.0%. All specificities were 98.8% to 100.0%. Coefficients of variation indicated good intralaboratory and interlaboratory repeatability and reproducibility but increased for decreasing concentrations. Prediction models revealed a significant correlation for all variants between the predefined copy number and the observed semiquantitative index values, which reflect the samples' plasma mutation load. This study demonstrates an overall robust performance of the real-time PCR EGFRmutation test kit in plasma. Prediction models may be applied to estimate the plasma mutation load for diagnostic or research purposes.

Published
2018
Full Text
View/download PDF

35. EML4-ALK mutation in Austrian patients with NSCLC: A multicenter study.

Author

Hochmair, Maximilian J., primary, Setinek, Ulrike, additional, Efstathiades, Thomas, additional, Kirchbacher, Klaus, additional, Mohn-Staudner, Andrea, additional, Arns, Britt-Madeleine, additional, Gulesserian, Melina, additional, Dworan, Nina, additional, Breyer, Marie, additional, Patocka, Kurt, additional, and Burghuber, Otto, additional

Published
2013
Full Text
View/download PDF

36. Abstract 1067: Targeting the fibroblast growth factor receptor axis in malignant pleural mesothelioma

Author

Hoda, Mir Alireza, primary, Schelch, Karin, additional, Pirker, Christine, additional, Ghanim, Bahil, additional, Klikovits, Thomas, additional, Laszlo, Viktoria, additional, Setinek, Ulrike, additional, Filipits, Martin, additional, Dome, Balazs, additional, Hegedues, Balazs, additional, Marian, Brigitte, additional, Grasl-Kraupp, Bettina, additional, Klepetko, Walter, additional, Berger, Walter, additional, and Grusch, Michael, additional

Published
2012
Full Text
View/download PDF

41. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

Author

Fischer, Hendrik, primary, Taylor, Ninon, additional, Allerstorfer, Sigrid, additional, Grusch, Michael, additional, Sonvilla, Gudrun, additional, Holzmann, Klaus, additional, Setinek, Ulrike, additional, Elbling, Leonilla, additional, Cantonati, Heidelinde, additional, Grasl-Kraupp, Bettina, additional, Gauglhofer, Christine, additional, Marian, Brigitte, additional, Micksche, Michael, additional, and Berger, Walter, additional

Published
2008
Full Text
View/download PDF

43. Down-Regulation of Sprouty2 in Non–Small Cell Lung Cancer Contributes to Tumor Malignancy via Extracellular Signal-Regulated Kinase Pathway-Dependent and -Independent Mechanisms

Author

Sutterlüty, Hedwig, primary, Mayer, Christoph-Erik, additional, Setinek, Ulrike, additional, Attems, Johannes, additional, Ovtcharov, Slav, additional, Mikula, Mario, additional, Mikulits, Wolfgang, additional, Micksche, Michael, additional, and Berger, Walter, additional

Published
2007
Full Text
View/download PDF

44. Telomerase- and Alternative Telomere Lengthening–Independent Telomere Stabilization in a Metastasis-Derived Human Non–Small Cell Lung Cancer Cell Line: Effect of Ectopic hTERT

Author

Brachner, Andreas, primary, Sasgary, Soleman, additional, Pirker, Christine, additional, Rodgarkia, Chantal, additional, Mikula, Mario, additional, Mikulits, Wolfgang, additional, Bergmeister, Helga, additional, Setinek, Ulrike, additional, Wieser, Matthias, additional, Chin, Suet-Feung, additional, Caldas, Carlos, additional, Micksche, Michael, additional, Cerni, Christa, additional, and Berger, Walter, additional

Published
2006
Full Text
View/download PDF

47. Letters to the editor

Author

Marques, Wilson, primary, Barreira, Auilton Artunes, additional, Oh, Shin J., additional, Claussen, Gwendolyn C., additional, Wondrusch, Elizabeth, additional, Zifko, Udo, additional, Grisold, Wolfgang, additional, Drlicek, Markus, additional, Setinek, Ulrike, additional, St�bgen, Joerg-Patrick, additional, Venkatesh, Swamy, additional, Rao, Ambika, additional, Gupta, Ravinder, additional, Younger, David S., additional, Rosoklija, G., additional, Neinstedt, L. J., additional, Latov, N., additional, Jaffe, I. A., additional, and Hays, A. P., additional

Published
1996
Full Text
View/download PDF

49. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.

Author

Watzka, Stefan B, Setinek, Ulrike, Huber, Monika, Cantonati, Heidi, Lax, Franz, Watson, Sonja, Weigel, Günter, and Müller, Michael R

Abstract

Integrin-linked kinase (ILK) is a protein kinase that links integrins and growth factors to a range of signalling pathways. ILK expression and activity are increased in a variety of human cancers. However, little is known regarding the role of ILK in malignant pleural mesothelioma (MPM). In this study, we assessed the expression of ILK in samples of human MPM, and compared it with the expression of epidermal growth factor receptor (EGFR). Thirty-four samples of human malignant mesothelioma were stained with a polyclonal antibody against ILK. Two independent observers evaluated the morphological pattern and intensity of staining. The findings have been compared with the patient's characteristics. Most MPM and mesothelial cell proliferation samples (87.9%) showed cytoplasmic ILK staining of varying intensity. Normal mesothelial cells and normal lung parenchyma did not stain for ILK at all. Conversely, the percentage of positive EGFR staining was somewhat lower (75.8%). The ILK-positive patients were significantly older than the ILK-negative patients. Here we report for the first time that ILK is indeed expressed in malignant mesothelioma. For further validation of a causal association between ILK and neoplastic mesothelial transformation, these immunohistochemical results should be supplemented with clinical and molecular biological data.

Published
2008
Full Text
View/download PDF

50. Primary synovial sarcoma of the lung as an incidental finding.

Author

Watzka, Stefan B, Setinek, Ulrike, Prosch, Helmut, and Müller, Michael R

Abstract

Synovial sarcoma of the lung (SSL) is a very rare but aggressive primary lung tumor. Due to its unusual histological features, it can easily be misdiagnosed, if only small biopsies of the tumor are investigated. Here, we review two recent cases of SSL diagnosed and treated in our institution. The first case is a 37-year-old male with a round nodule in the right lower lobe; he underwent a lobectomy. Histologically, the nodule resembled a biphasic tumor. Cytogenetic analysis revealed a translocation t (X; 18), and the diagnosis of primary SSL could be established. The patient is alive and disease-free since 45 months following surgery. The second case is a 41-year-old male with a cystic lesion in the right lower lobe, removed by video-assisted thoracic surgery (VATS) segmentectomy. In the tumor tissue, spindle cell-rich and cystic structures could be found, together with epithelial elements. Because the tumor contained also a translocation t (X; 18), it could be diagnosed as monophasic SSL. The patient is alive and disease-free since 11 months. Since rare diseases of the lung may present as subtle and focal changes, complete removal of suspect pulmonary lesions is always advisable.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results